One-third of patients with PSA levels below 0.2 ng/mL after radical prostatectomy have recurrent disease identifiable by PSMA PET. More than one-third of patients with PSA levels less than 0.5 ng/mL ...

Telix Pharmaceuticals Limited today announces that its prostate cancer PET[1] imaging agent Illuccix® (kit for the preparation of gallium-68 gozetotide injection) has been granted marketing ...

Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...

A 61-year-old patient, initially presenting with urinary complaints, has undergone Stereotactic Body Radiation Therapy (SBRT) for prostate cancer at KMC Hospital Attavar Oncology Centre (KMCHAOC) in ...

See α-Synuclein. Candidate tracer SY08 detects α-synuclein deposits in the brainstem (right) and parietal cortex (left) of ...

Cardinal is using its own cyclotron installations to produce Gozellix for distribution across a range of US locations.

In this video Thomas Wisniewski, MD, director of NYU Langone’s Alzheimer’s Disease Research Center, discusses recent advancements in Alzheimer's disease care.

Regional West invites the community to attend its new PET/CT suite open house on Tuesday, April 22, 4 to 7 p.m., in the ...

Guidelines created by a multi-disciplinary panel of specialists focus on implementation of novel treatments and technologies for which level 1 evidence is lacking.

A new FDA approval has brought a renewed sense of hope as an innovative new treatment approach is now available to ...

New research highlights the significance of timing and tumour location when evaluating PSMA PET scans following radiotherapy ...

Telix Pharmaceuticals is leveraging its success with Illuccix to build a diversified theranostic platform, driving long-term ...